Oak Hill Bio Secures $32.5 Million in Latest Series A Funding Round

Oak Hill Bio secured $32.5 million in its latest Series A, adding another data point to the Healthcare & Life Sciences funding market.

Oak Hill Bio Raises $32.5 million in Funding

Oak Hill Bio is a Digital Health company focused on advance rugonersen for Angelman syndrome.

Investors Behind the Funding

The round was backed by Takeda. Funding Intelligence tracks this investor activity alongside sector momentum, co-investor patterns, and recent comparable raises.

Company Profile and Market Context

Oak Hill Bio operates in Healthcare & Life Sciences. Oak Hill Bio's Series A round shows investors are still backing digital health platforms with real scale narratives. At $33M, the deal suggests buyers want category leaders that can turn AI, automation, or workflow leverage into durable enterprise demand.

Strategic Use of Funds

advance rugonersen for Angelman syndrome

Looking Ahead

Oak Hill Bio Raises $32.5 Million Series A Financing to

Source reference: original announcement/article.